Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 27395 participants.
Also called NCT01776424
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 27,395 participants
- Registry
-
NCT01776424 -
2012-004180-43
-
- Main results
- Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
- Other papers using this trial's data
- Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial
- Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease
- Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial
- Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease
- Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial
- Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial
- Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial
- Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin
- Monitoring Emerging Data From the COMPASS Trial of an Antithrombotic Agent
- Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease
- Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial
- Results of the COMPASS Trial Analyzed Using Win Ratio Compared With Conventional Analytic Approaches
- Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial
- Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial
- Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial
- Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial
- Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease
- Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial
- Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
- Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
- Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study
- Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial
- Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin
- Skeletonized vs Pedicled Internal Mammary Artery Graft Harvesting in Coronary Artery Bypass Surgery: A Post Hoc Analysis From the COMPASS Trial
- Stroke Outcomes in the COMPASS Trial
- Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease
- The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease
- Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Czechia, Denmark, Ecuador, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Malaysia, Netherlands, Philippines, Poland, Romania, Russia, Slovakia, South Africa, South Korea, Sweden, Switzerland, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01776424. Randomized; quadruple masking; primary purpose prevention. Start 2013-02-28 (actual); primary completion 2017-07-21 (actual). Results posted on 2018-10-05.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
- Acronym
- COMPASS
- Condition
- Prevention & Control
- Intervention (Drug)
- Rivaroxaban (Xarelto, BAY59-7939)
- Intervention (Drug)
- Rivaroxaban (Xarelto, BAY59-7939)
- Intervention (Drug)
- Aspirin
- Intervention (Drug)
- Aspirin placebo
- Intervention (Drug)
- Rivaroxaban placebo
- Intervention (Drug)
- Pantoprazole
- Intervention (Drug)
- Pantoprazole placebo
- Lead sponsor
- Bayer
- Collaborator
- Population Health Research Institute
- Collaborator
- Janssen Research & Development, LLC
Record details
- Record id
cardio:ct-nct01776424- Content hash
5a3152d0beaeb09b6e4181e936e59296a5736b6a3a3aa7420bee4991b782aaac